Lyka Labs share news, announcements and annual reports
NSE: LYKALABSBSE: 500259Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 2 Nov 2026. Previous close ₹76.60.
2 Nov: open ₹76.00, high ₹76.00, low ₹75.07
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹271 Cr2,310th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.83
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −4.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −3.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.47
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 15,895
Lyka Labs share news and announcements
1,493 announcements, routine notices left out, newest first. Page 12 of 30.
Oct 2021
29 Oct · Board meeting
22 Oct · Board meeting
20 Oct · Lyka Labs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly Click ....
Shareholding for the Period Ended September 30, 202111 Oct · No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Statement Of Investor Complaints For The Quarter Ended September 2021
Sep 2021
Aug 2021
4 Aug · Management
4 Aug · Results
Jul 2021
31 Jul · Results
Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)30 Jul · Meeting
19 Jul · Lyka Labs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2021. For more details, kindly Click ....
Shareholding for the Period Ended June 30, 202113 Jul · No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 1 0 1 0
Statement Of Investor Complaints For The Quarter Ended June 20218 Jul · Reg. 34 (1) Annual Report
8 Jul · Meeting
Jun 2021
15 Jun · Related Party Transactions
15 Jun · Disclosure Under Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
3 Jun · Legal
Exchange has sought clarification from Lyka Labs Limited with respect to manufacture and market of Liposomal Amphotericin B Injection.On basis of above the Company is required to clarify following:1. Date of launch;2. Whether caters to domestic/ international market;3. Name of the countries in which the product is launched (in case of international).The response of the Company is awaited.2 Jun · Declaration Under Regulation 33 Of SEBI (LODR) Regulations, 2015
2 Jun · Board meeting
2 Jun · Board meeting
2 Jun · Results